CCM
AMRX icon

CAAS Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

CAAS Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-731,528
Closed -$4.92M – 1031
2021
Q1 		$4.92M Buy
+731,528
New +$4.05M 0.05% 360

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

CAAS Capital Management's AMRX Position: Q2 2021 in Review

CAAS Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2021, closing a stake of 731,528 shares — an estimated $4.92M sold.

CAAS Capital Management first reported a position in AMRX in Q1 2021 and held it in 1 quarter. The position peaked at $4.92M in Q1 2021. 160 funds tracked by Wall St. Rank hold AMRX as of Q2 2021.

  • CAAS Capital Management reported no remaining Amneal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 731,528 Amneal Pharmaceuticals shares in Q2 2021, an estimated $4.92M.
  • CAAS Capital Management first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Amneal Pharmaceuticals position peaked at $4.92M in Q1 2021.
  • 160 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.